Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Citarinostat - Celgene Corporation

Next Previous
Drug Profile

Citarinostat - Celgene Corporation

Alternative Names: ACY 241; CC-96241; HDAC-IN-2

Latest Information Update: 29 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital
  • Developer Celgene Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • No development reported Malignant melanoma; Non-small cell lung cancer; Smoldering multiple myeloma; Solid tumours

Most Recent Events

  • 09 Dec 2023 Efficacy and adverse events data from a phase I trial in Smoldering Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 29 Jan 2023 Massachusetts General Hospital in collaboration with OncoPep and Celgene completes enrolment in its phase I trial for Multiple myeloma in US (NCT02886065)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top